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Abstract 
Background 
Type 2 diabetes is an independent risk factor for chronic liver disease, however disease 
burden estimates and knowledge of prognostic indicators are lacking in community 
populations. 
Aims 
To describe the prevalence and incidence of clinically significant chronic liver disease 
amongst community-based older people with type 2 diabetes and to determine risk factors 
which might assist in discriminating patients with unknown prevalent or incident disease.   
Design 
Prospective cohort study 
Methods 
939 participants in the Edinburgh Type 2 Diabetes Study underwent investigation including 
liver ultrasound and non-invasive measures of NASH, hepatic fibrosis and systemic 
inflammation.  Over 6-years, cases of cirrhosis and hepatocellular carcinoma were collated 
from multiple sources.   
Results 
Eight patients had known prevalent disease with 13 further unknown cases identified 
(prevalence 2.2%) and 15 incident cases (IR 2.9/1000person-years).  Higher levels of 
systemic inflammation, NASH and hepatic fibrosis markers were associated with both 
unknown prevalent and incident clinically significant chronic liver disease (all p<0.001).   
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Conclusions 
Our study investigations increased the known prevalence of clinically significant chronic 
liver disease by over 150%, confirming the suspicion of a large burden of undiagnosed 
disease.  The disease incidence rate was lower than anticipated, but still much higher than the 
general population rate.  The ability to identify patients both with and at risk of developing 
clinically significant chronic liver disease allows for early intervention and clinical 
monitoring strategies.  Ongoing work, with longer follow-up, including analysis of rates of 
liver function decline, will be used to define optimal risk prediction tools. 
[244] 
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Introduction 
Chronic liver disease (CLD) due to non-alcoholic fatty liver disease (NAFLD) in community 
populations represents a major challenge for general practitioners and a growing burden for 
healthcare services1. Of the 25% of the UK population now categorised as obese, most will 
have NAFLD2 and about 10% of these people have been diagnosed in community studies to 
have evidence of advanced liver fibrosis that leads to cirrhosis3. Of patients with cirrhosis (all 
cause), 5±20% will develop hepatocellular carcinoma (HCC) in 5 years4. Type 2 diabetes, 
which is increasing in frequency in parallel with obesity, is strongly associated with NAFLD 
but data on the progression to cirrhosis and HCC in community-based patients with diabetes 
is limited. 
Three major independent reports have highlighted the need for the early detection of liver 
disease2, 5, 6. The ability to identify patients with and at risk of developing clinically 
significant CLD (CS-CLD) would promote early intervention strategies and guide clinical 
follow-up, ensuring timely detection of cirrhosis where assimilation into surveillance 
programmes for HCC and varices as well as screening for cardiovascular disease has been 
shown to improve patient outcomes. Despite this, the existing diagnostic pathways for 
detection and onward referral of suspected CLD are based on traditional liver enzyme tests 
which lack accuracy and contribute to late diagnosis.  
Using a population-based cohort of approximately 1000 patients with type 2 diabetes (The 
Edinburgh Type 2 Diabetes Study7) we employed an extensive screening programme 
(including liver ultrasound and non-invasive measures of non-alcoholic steatohepatitis 
[NASH], hepatic fibrosis and systemic inflammation) for clinically significant liver disease in 
order to investigate the true burden of disease.  Over 6-years, cases of cirrhosis, HCC and 
gastro-oesophageal varices were collated from multiple sources.   
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Within the diabetic population annual liver enzyme checks are commonly performed, but 
there are no clear and consistent national guidelines on their application and interpretation, 
particularly in the community setting.  Despite this, they remain the main trigger for referral 
to specialist liver clinics. Using standard liver enzyme assessment and liver ultrasound scan 
(USS) to diagnose hepatic steatosis, we identified patients at potential risk of CS-CLD and 
followed them up prospectively to collect data on clinical outcomes.   
Our aim was to describe the prevalence and incidence of CS-CLD amongst older people with 
type 2 diabetes and to determine whether the detection of abnormal liver enzyme levels 
and/or the presence of hepatic steatosis on USS in people with type 2 diabetes might assist in 
discriminating those patients who subsequently go on to develop CS-CLD.  Finally, we 
investigated a wide range of potential risk factors and biomarkers, including complications of 
diabetes and markers of advanced CLD, which might be useful in identifying at-risk subjects. 
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Methods 
The Edinburgh Type 2 Diabetes Study (ET2DS) 
Full methods of the ET2DS have been published elsewhere7.   Briefly, in 2006/7 patients 
aged 60-75 years with type 2 diabetes were randomly selected from the Lothian Diabetes 
Register (LDR), a comprehensive register of patients with diabetes living in Lothian, 
Scotland, and invited to participate in the ET2DS.   
1066 men and women attended a baseline research clinic and were enrolled into the study.  
This study population has been shown to be largely representative of all patients randomly 
selected from the LDR and therefore of the target population of older men and women with 
type 2 diabetes living in the general population8. 
All survivors were invited to re-attend for clinical and liver investigation at year 1 (2007/8) 
and at year 4 (2010/11) with 939 (dead n=15, unable to contact n=19, unwilling/unable n=93) 
and 831 study participants attending, respectively. 
Clinical and laboratory examination 
Details of all the research clinics held at the Wellcome Trust Clinical Research Facility, 
Western General Hospital, Edinburgh, UK have been described previously7, 9.  In brief, 
fasting venous blood sampling, physical examination and abdominal USS were undertaken.  
A liver screen (including viral hepatitis serology, alpha-feto protein [AFP], liver 
autoantibodies, serum ferritin) was undertaken if the patient met the criteria for referral to 
specialist Hepatology services (see below) or if hepatic steatosis was present on USS and the 
participant had never previously had a liver screen. 
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All biochemical analytes were measured at the time of clinic attendance using a Vitros Fusion 
chemistry system (Ortho Clinical Diagnostics, Bucks, UK) at the Western General Hospital 
(Edinburgh, UK).    
Biomarkers of liver injury 
A wide range of hepatic biomarkers were assessed including those indicating non-specific 
liver injury (liver enzymes: alanine aminotransferase [ALT], aspartate aminotransferase 
[AST] and gamma-glutamyl aminotransferase [GGT]), steatosis (USS-graded liver fat10), 
NASH (cytokeratin-18 [CK18]), surrogate measures of advanced portal hypertension (spleen 
size and platelet count), and liver fibrosis (AST to Platelet Ratio Index [APRI]11, AST:ALT 
ratio, Enhanced Liver Fibrosis [ELF] score12, Fibrosis-4 score [FIB-4]13, hyaluronic acid 
[HA] and NAFLD Fibrosis Score [NFS]14). 
CK18 and ELF were measured in stored serum samples (-80oC) as previously described15.   
Abnormal liver enzymes were defined as: i) abnormal - greater than the upper limit of normal 
(ULN) ± ALT >50U/L, AST >45 U/L, GGT >55U/L; ii) highly abnormal - greater than 2x 
ULN for ALT, AST, GGT; and iii) greater than recently proposed sex specific cut-offs for 
ALT ± males >30U/L, females >19U/L16.   
Serum marker panels for hepatic fibrosis were calculated as in original publications.  
Identification of liver disease 
Identification of liver disease is described in Figure 1. Definite (prevalent or incident) CS-
CLD was a composite outcome defined as a diagnosis of cirrhosis, HCC (with confirmatory 
radiology) or gastro-oesophageal varices (with confirmatory endoscopy) recorded in the 
SDWLHQWV¶PHGLFDOUHFRUGV Research study referral criteria for referral to specialist Hepatology 
services were designed in conjunction with an experienced consultant Hepatologist (Figure 
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1A), prevalent and incident CS-CLD was identified using a two-stage process across multiple 
sources (Figure 1B) and CS-CLD was defined as in Figure 1C.   
Data analysis 
Data were analysed using SPSS v19.0 (SPSS Inc., Illinois, USA).  Variables that were not 
normally distributed were, where necessary, transformed and analysed on a logarithmic scale.   
We describe the prevalence (both known and unknown) at the start of the study and 
subsequent incident CS- CLD.  For initial analyses, all participants without known prevalent 
CS-CLD were included.   
Exploratory analysis of potential risk factors and biomarkers associated with the development 
of advanced liver disease was undertaken using : patient characteristics, diabetes history and 
treatment, metabolic variables, established risk factors for CLD, markers of liver injury (non-
specific, steatosis, NASH, advanced portal hypertension and liver fibrosis), and markers of 
systemic inflammation. Cox regression was used to investigate the association of potential 
risk factors with CS-CLD. 
Ethical approval was obtained from the Lothian Research Ethics Committee and all subjects 
gave written informed consent.  
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Results 
Subject characteristics 
Participant attendance is shown in Figure 2.  Clinical follow-up data was available for all 939 
year 1 clinic attendees.  Characteristics of the study population are shown in Table 1. 
Prevalent clinically significant chronic liver disease 
Eight patients had known prevalent CS-CLD and were excluded from the investigation of 
unknown prevalent disease (n=931, Figure 2A)17.   
Following the year 1 investigations, 13.4% (125/931) of participants met the research study 
protocol criteria as high-risk for the presence of liver disease and were referred to 
Hepatology.  Risk factors for referral are shown in Table 1. 
Of these, 52 (41.6%) were offered an appointment at Hepatology clinic and the remainder 
returned to standard care after triage by a consultant Hepatologist.  The majority of those not 
seen had low level titres of positive autoantibodies  or isolated mildly elevated liver 
enzymes only (<2xULN).   
Of those referrals seen, 31 (59.6%) were immediately discharged following initial assessment 
on the basis of having either simple fatty liver with low risk for the presence of significant 
liver fibrosis (according to non-invasive marker criteria) and/or false positive indicators of 
CS-CLD (e.g. platelets <150x109/L but no portal hypertension) as determined by a consultant 
Hepatologist.  Twenty-one participants (40.4) remain under active Hepatology follow-up. 
As a consequence of the year 1 investigations, 13 (1.4%) patients were diagnosed with 
previously unknown prevalent CS-CLD (including one HCC, the remainder cirrhosis).  The 
reasons for their initial referral were wide-ranging.  
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Risk factors associated with unknown prevalent cases were elevated liver enzymes (but not 
ALT), inflammatory markers, markers of NASH and hepatic fibrosis (all p <0.01, Tables 2 
and 3).   
Overall the prevalence of CS-CLD was 2.2% (known plus unknown). 
Development of incident clinically significant CLD 
918 patients (Figure 2B) did not have prevalent CS- CLD.   
Over a mean follow-up period of 5.6 years (sd 1.0, total 5156 person-years) there were 15 
incident cases of CS- CLD, IR 2.9 /1000 person-years.  These comprised cirrhosis n=14 (2.7 
/1000 person-years), HCC n=4 (0.8 /1000 person-years), and gastro-oesophageal varices n=5 
(1.0 /1000 person-years), with some patients having more than one complication.  
Patients identified as potentially high risk after the year 1 investigations were more likely to 
develop CS- CLD than those not thought to have liver disease (IR 10.9 vs 1.8 /1000 person-
years, p=0.001).  However, of the incident 15 patients that developed CS-CLD less than half 
(n=7, 46.7%) were identified as high-risk by the extensive liver-related investigations at the 
year 1 clinic.  Of the incident HCC, only 1 (25.0%) occurred in a participant identified 
through our year 1 investigations.  The majority of cases of varices (n=3, 60.0%) were 
identified through entry into an endoscopic surveillance programme. 
Rates of incident CS-CLD were significantly higher in those: seen in the Hepatology clinic 
(IRR 18.7, 95%CI 6.5-54.0, p<0.001), with abnormal liver enzymes (IRR 5.7, 95%CI 2.0-
16.0, p=0.001) and with very abnormal liver enzymes (IRR 16.3, 95%CI 5.2-50.9, p<0.001).  
Individuals with hepatic steatosis or elevated liver enzymes as defined by the lower revised 
laboratory reference ranges had incidence rates of CS-CLD not significantly different to those 
without (IRR 2.9, p=0.096 and IRR 1.2, p=0.800 respectively).   
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Patients with abnormal liver enzymes at the year 1 investigation were more likely to develop 
CS-CLD, (normal 7/776, 0.9%; abnormal 3/113, 2.7%; very abnormal 5/26, 19.2%; 
p<0.001).  In those developing CS-CLD, mean/median levels of liver enzymes were higher, 
however they remained broadly within normal laboratory limits for transaminases (ALT 44.4 
U/L, AST 46.0 U/L), with median GGT levels above the upper limit of normal (median 62 vs 
16 U/L, p<0.001) (Table 2), overall 47% of those with incident CS-CLD had normal liver 
enzymes (Table 3).   
Tables 2 and 3 show the associations between potential risk factors and incident CS-CLD.  
Known causes of liver disease (including alcohol) were similar in both groups (p=0.123).  
Higher levels of markers of systemic inflammation were associated with an increased 
incidence of CS-CLD (ln CRP HR 1.66 p=0.026, ln IL-6 HR 2.86 p=0.002, ln TNF-D HR 
2.12 p=0.017) 
Nearly all patients (80.0%) with incident CS-CLD had hepatic steatosis at the start of the 
study, although this was not statistically significant.  All of the continuous markers of NASH 
and hepatic fibrosis (except AST:ALT ratio) were higher in those with incident CS-CLD than 
in those who did not. 
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Conclusions 
We conducted the only large prospective community-based study of older patients with type 
2 diabetes. The prevalence of CS- CLD at baseline was 2.2% (0.9% diagnosed clinically prior 
to enrolment and 1.4% identified by study investigations).  The incidence of CS-CLD was 
1.4% over nearly 6 years (IR 2.9 /1000 person-years).   
Existing estimates of CS-CLD frequency are limited by reliance on confirmatory liver biopsy 
in secondary care populations or in community-based cohorts by the use of a single screening 
modality (e.g.  FibroTest18, transient elastography19) each with their own challenges; for 
example liver enzymes have low diagnostic accuracy, non-invasive fibrosis markers (e.g.  
ELF, NFS) have poor positive predictive values for later stages of CLD12, 14, ICD codes only 
identify hospitalised cases with decompensation, and biopsy has marked ascertainment bias.  
Accordingly, in the general population, the prevalence of advanced fibrosis in NAFLD  
ranged from 0-12% in a single study depending on the markers used20, and there is even 
greater discordance between different studies on CS-CLD prevalence.  Therefore, we used a 
multimodal approach to comprehensively phenotype our cases and maximize detection CS-
CLD.   
Our findings support the suggestion that NAFLD is an under-diagnosed chronic disease21 
despite patients with type 2 diabetes having, as a minimum, annual clinical reviews including 
liver enzyme tests.  Our multimodal diagnostic approach increased the prevalence by more 
than 150% through the diagnosis of unknown CS-CLD, of which almost 70% was 
attributable to NAFLD.  However, it was a labour intensive process with 14% of the study 
participants referred to a consultant Hepatologist.  In the majority of these patients, simple 
laboratory tests were abnormal (e.g.  liver enzymes above the ULN, low platelet count) 
although, typically, values were only marginally elevated.   
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Reassuringly, despite a relatively high prevalence of uncomplicated NAFLD at year 1 there 
were only a small number of patients who went on to develop incident CS-CLD after 6 years 
(2.9 /1000 person-years).  In 103 NAFLD patients followed by Adams et al22 for a mean of 
3.2 years, the fibrosis progression rate was 0.35 stages/year in those with diabetes.  This is 
high compared to our cohort as it equates to a potential 2-stage advancement over the 6 year 
follow-up of our cohort in those with NAFLD.  In NASH populations,  32% of subjects 
progressed fibrosis score over 3 years23 and 31% had progressive fibrosis24, although no 
participant developed cirrhosis during 4 years of follow-up.   
The only aspect of diabetes history to be associated with the development of CS-CLD was 
the use of insulin (HR 9.08).  Hyperinsulinemia associated with T2DM is a risk factor for 
NASH, hepatic fibrosis and HCC. Insulin stimulates hepatic stellate cell proliferation and 
collagen synthesis in vitro and therefore, by extension, exogenous insulin therapy could 
promote liver fibrosis in vivo25. Our data reinforces the known association between the 
presence of diabetes  and increased the risk of HCC26.  Moreover, Scottish Cancer Registry 
data showed that within the whole Scottish population aged 60-75 the IR for liver-related 
cancer (including biliary) in 2012 was 0.3/1000 person-years27, which is substantially lower 
than the rate for HCC alone in our cohort (0.8/1000 person-years).  
Participants in the least deprived SIMD quintile had an incidence rate of CS-CLD 74% lower 
than those in the most deprived quintile. This unadjusted finding may represent confounding 
by other factors such as alcohol and obesity. Previous studies into the relationship between 
chronic liver disease and deprivation have found any associations were lost after adjustment 
for such risk factors28. 
Critically, for clinical practice, the majority of incident CS-CLD had normal liver function 
tests with no steatosis.  Whilst those with abnormal liver enzymes per se were more likely to 
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develop CS-CLD, the mean levels of liver enzymes in those that did were still within the 
normal laboratory reference range.  It may be that given the high prevalence of steatosis in 
the cohort that it may add little risk of CS-CLD beyond the risk conferred by type 2 diabetes 
alone. 
The main limitation to this study is the lack of liver biopsy, although this represents an 
LPSHUIHFWµJROGVWDQGDUG¶WHVWIRUthe diagnosis and staging of NAFLD and is impractical in 
community studies with a low prevalence of CS-CLD. Additionally, we would argue that our 
non-invasive liver assessment is more applicable to clinical practice and is unlikely to have 
missed CS-CLD due to the use of validated cut-offs and robust triage for referral to a 
consultant Hepatologist.  
This work suggests that there is little benefit in performing liver USS of patients similar to 
the study cohort, where the finding of hepatic steatosis could be predicted and provides no 
indication of future disease progression. 
For the first time, we have evaluated the utility of extensive but simple targeted investigation 
using routinely available clinical tests in order to identify those at high risk of both immediate 
and future CS-CLD.  We plan to conduct longer term follow-up to capture future incident 
liver related events.  Of particular interest will be how the rate of change of potential 
biomarkers in earlier stages of CLD can be used to predict future development of CS-CLD. 
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Tables 
Table 1.  Study population.  Values are mean (sd), median (IQR) or % (n). 
  
Study 
population 
n=923 
 
Met 
Hepatology 
referral 
criteria 
n=125 
P 
[vs. not 
referred] 
 
Seen by 
Hepatology 
services 
n=52 
P 
[vs. not 
seen] 
         
Age, years  68.9 (4.2)  69.3 (4.3) 0.224  69.3 (4.6) 0.423 
Sex, % male  52.3% (483)  40.8 (51) 0.007  40.4 (21) 0.087 
SIMD quintile, % I  11.4 (105)  9.6 (12) 
0.041 
 9.6 (5) 
0.031 
 V  34.3 (317)  31.2 (39)  25.0 (13) 
         
Random glucose, mmol/L  6.89 (2.3)  7.60 (3.0) 0.003  7.93 (3.3) 0.021 
HbA1c, %  7.20 (1.1)  7.37 (1.2) 
0.046 
 7.69 (1.3) 
0.008 
HbA1c, mmol/mol  55.2 (11.7)  57.1 (12.7)  60.5 (14.6) 
Duration of diabetes, % <5 years  25.7 (235)  20.0 (25) 0.124  17.3 (9) 0.191 
Diabetes 
treatment:  
Diet, % 
 
19.5 (180)  19.2 (24) 1.000 
 
19.2 (10) 1.000 
 OAHA, %  64.8 (598)  63.2 (79) 0.688  59.6 (31) 0.456 
 Insulin, %  15.7 (145)  17.6 (22) 0.511  21.2 (11) 0.245 
         
Retinopathy, 
% 
Mild 
Moderate/severe 
 27.9 (254) 
4.4 (40) 
 
24.2 (30) 
7.2 (9) 
0.182 
 25.0 (13) 
11.5 (6) 
0.035 
Chronic kidney disease
a
, %  19.6 (179)  22.8 (28) 0.393  27.5 (14) 0.149 
Cardiovascular disease
b
, %  36.9 (338)  37.6 (47) 0.842  38.5 (20) 0.769 
         
BMI, kg/m
2
  31.3 (5.7)  31.7 (6.1) 0.411  32.0 (6.6) 0.414 
Total cholesterol, mmol/L  4.4 (0.8)  4.3 (0.8) 0.021  4.1 (0.8) 0.690 
Triglycerides, mmol/L  1.66 (0.9)  1.74 (1.0) 0.305  1.50 (0.6) 0.073 
sBP, mmHg  138.2 (18.5)  140.6 (18.6) 0.115  138.7 (17.1) 0.845 
         
Known risk factor for liver 
disease
c
, % 
 
20.9 (193)  31.2 (39) 0.004 
 
34.6 (18) 0.021 
Alcohol excess
d
, %  12.8 (118)  20.8 (26) 0.006  21.2 (11) 0.084 
Hepatotoxic medication
e
, %  9.2 (6)  10.4 (13) 0.618  11.5 (6) 0.467 
Positive autoantibodies
f
, %  0.7 (6)  3.2 (4) 0.005  3.8 (2) 0.046 
BMI body mass index; IQR inter-quartile range; OAHA oral anti-hyperglycaemic agent; sBP systolic blood 
pressure; sd standard deviation; SIMD Scottish Index of Multiple Deprivation 
a Defined as estimated glomerular filtration rate <60ml/min. 
b Defined as of myocardial infarction, angina, coronary intervention, intermittent claudication, peripheral artery 
intervention, stroke, transient ischaemic attack or carotid endarterectomy. 
c
 Defined as any of d-f below. 
d
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior 
alcohol problem. 
e Defined as the use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or 
tamoxifen within the 6 months prior to the liver assessment. 
f Defined as ASMA titre >1:160 or AMA titre >1:40  
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Table 2. Potential demographic, diabetes and metabolic risk factors for the development of CS-CLD.  Values are % (n), odds ratios and hazard ratios. 
  
No CS-CLD 
n=903 
Unknown 
prevalent 
CS-CLD n=13 
OR (95% CI) for 
unknown prevalent 
CS-CLD 
p 
 
Incident CS-CLD 
n=15 
HR (95% CI) for 
incident CS-CLD 
p 
Age, years  68.9 (4.2) 69.5 (4.9) 1.04 (0.91,1.18) 0.600  69.8 (4.1) 1.07 (0.94,1.21) 0.306 
Sex, % male  52.5 (474) 30.8 (4) 2.49 (0.76,8.13) 0.132  40.0 (6) 1.93 (0.69,5.45) 0.213 
SIMD quintile: I, %  11.2 (101) 7.7 (1) - -  33.3 (5) Ref  
 V,%  34.9 (315) 0 (0) -   26.7 (4) 0.26 (0.07,0.97) 0.044 
Duration of diabetes >5 years, %  73.7 (660) 76.9 (10) 1.19 (0.32,4.35) 0.796  93.3 (14) 5.30 (0.70,40.34) 0.107 
Fasting glucose, mmol/L  6.87 (2.3) 7.53(3.2) 1.11 (0.91,1.35) 0.301  6.98 (2.8) 1.21 (0.78,1.88) 0.405 
HbA1c, 
%  7.19 (1.1) 7.34 (0.8) 1.13 (0.70,1.84) 
0.615 
 7.53 (1.5) 
1.02 (0.98,1.06) 0.405 
mmol/mol  55.1 (11.6) 56.7 (8.3) 1.01 (0.97,1.06)  58.8 (15.9) 
Diabetes 
treatment: 
Diet, % 
 
19.7 (178) 15.4 (2) Ref  
 
6.7 (1) Ref  
 OAHA, %  65.1 (588) 46.2 (6) 1.06 (0.22,5.15) 0.943  53.3 (8) 2.50 (0.31,20.0) 0.388 
 Insulin, %   15.2 (137) 69.2 (9) 2.60 (0.47,14.4) 0.274  40.0 (6) 9.08 (1.09,75.5) 0.041 
BMI, kg/m
2
  31.2 (5.6) 33.4 (6.7) 1.06 (0.98,1.16) 0.161  34.8 (7.4) 1.09 (1.02,1.17) 0.016 
Cholesterol, mmol/L  4.2 (0.8) 3.9 (0.5) 0.68 (0.32,1.43) 0.310  3.9 (0.8) 0.66 (0.33,1.34) 0.248 
Triglycerides, mmol/L  1.67 (0.9) 1.25 (0.3) 0.39 (0.14,1.11) 0.078  1.46 (0.4) 0.70 (0.32,1.54) 0.371 
CRP
a
, mg/L  1.69 (0.8-3.9) 2.72 (1.4-11.6) 1.83 (1.14,2.94) 0.013  3.98 (1.9-13.6) 1.66 (1.06,2.60) 0.026 
          
CRP C-reactive protein; CS-CLD clinically significant chronic liver disease; HR hazard ratio; OR odds ratio; sd standard deviation; SIMD Scottish Index of Multiple 
Deprivation. 
CS-CLD defined as clinically significant disease: incident cirrhosis, hepatocellular carcinoma or gastro-oesophageal varices.   
a
 Analysed on the Ln scale: odds and hazard ratios for a one unit increase in the ln of the risk factor 
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Table 3. Potential liver injury related risk factors for the development of CS-CLD.  Values are % (n), odds ratios and hazard ratios. 
  
No CS-CLD 
n=903 
Unknown 
prevalent 
CS-CLD n=13 
OR (95% CI) for 
unknown prevalent 
CS-CLD 
p  
Incident CS-CLD 
n=15 
HR (95% CI) for 
incident CS-CLD 
p 
ALT, U/L  33.3 (12.7) 39.0 (12.6) 1.03 (1.00-1.06) 0.108  44.4 (23.6) 1.04 (1.01,1.06) 0.002 
ALT >50 U/L, %  7.8 (70) 23.1 (3) 3.56 (0.96,13.2) 0.058  40.0 (6) 6.69 (2.38,18.8) <0.001 
AST, U/L  30.0 (9.5) 49.7 (12.6) 1.09 (1.06-1.13) <0.001  46.0 (23.7) 1.07 (1.04,1.09) <0.001 
AST >45 U/L, %  6.8 (61) 69.2 (9) 30.8 (9.22,102.9) <0.001  40.0 (6) 8.30 (2.94,23.43) <0.001 
GGT
a
, U/L  16.0 (10.0-26.0) 55.0 (34.0-103.0) 5.35 (2.91,9.83) <0.001  62.0 (21.5-185.0) 3.56 (2.17,5.83) <0.001 
GGT >55 U/L, %  7.9 (71) 69.2 (9) 26.2 (7.87,87.1) <0.001  53.3 (8) 13.2 (4.79,36.6) <0.001 
CK18
a
, U/L  100.6 (76.2-135.5) 152.7 (143.1-207.9) 3.42 (1.59,7.34) 0.002  127.6 (83.4-586.5) 4.10 (2.08,8.06) <0.001 
Hepatic steatosis, %  56.8 (513) 46.2 (6) 0.65 (0.22,1.95) 0.445  80.0 (12) 2.93 (0.83,10.38) 0.096 
APRI*  0.24 (0.19-0.32) 0.67 (0.35-0.92) 87.7 (20.8,369.6) <0.001  0.39 (0.29-0.88) 20.4 (6.81,61.0) <0.001 
AST:ALT  0.95 (0.3) 1.33 (0.3) 2.55 (1.22,5.34) 0.013  1.10 (0.3) 1.56 (0.93,2.64) 0.094 
AST:ALT ratio >1, %  35.7 (320) 76.9 (10) 6.00 (1.64,22.0) 0.007  60.0 (9) 3.67 (1.29,10.44) 0.015 
ELF score  8.9 (0.8) 10.9 (1.0) 4.38 (2.20,8.70) <0.001  10.2 (1.0) 1.64 (1.30,2.06) <0.001 
FIB4 score  1.50 (0.6) 3.96 (2.0) 7.81 (3.93,15.5) <0.001  2.56 (1.3) 4.08 (2.71,6.15) <0.001 
HA
a
, micrg/L  50.6 (34.8-81.4) 220.3 (177.9-318.9) 16.4 (5.35,50.1) <0.001  183.2 (78.9-230.6) 5.80 (2.60,13.0) <0.001 
NFS  -0.40 (1.1) 1.38 (1.5) 3.99 (2.36,6.73) <0.001  0.74 (1.0) 2.18 (1.54,3.09) <0.001 
Spleen >13 cm, %  4.1 (37) 69.2 (9) 52.5 (15.5,178.5) <0.001  0 -  
Platelets <150x10
9
/L, %  3.0 (27) 46.2 (6) 27.3 (8.59,86.6) <0.001  14.3 (2) 4.36 (0.97,19.6) 0.055 
Known risk factor for liver 
disease
b
, % 
 
20.7 (187) 30.8 (4) 1.70 (0.52,5.59) 0.488 
 
40.0 (6) 2.44 (0.87,6.85) 0.091 
Alcohol excess
c
, %  12.6 (113) 23.1 (3) 2.09 (0.57,7.71) 0.268  20.0 (3) 1.63 (0.46,5.77) 0.451 
ALT alanine aminotransferase; APRI Aspartate to Platelet Ration Index; AST aspartate aminotransferase; CK18 cytokeratin-18; CS-CLD clinically significant chronic liver 
disease; ELF Enhanced Liver Fibrosis panel; FIB4 Fibrosis-4 Score; GGT gamma glutamyltransferase; HA hyaluronic acid; HR hazard ratio; NFS NAFLD Fibrosis Score; 
OR odds ratio. 
CS-CLD defined as clinically significant disease: incident cirrhosis, hepatocellular carcinoma or gastro-oesophageal varices.   
a
 Analysed on the Ln scale: odds and hazard ratios for a one unit increase in the ln of the risk factor 
b
 Defined as any of: alcohol excess (females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem), hepatotoxic medication 
use (use of (non-topical) glucocorticoids for >1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the liver assessment) or positive 
autoantibodies (ASMA titre >1:160 or AMA titre >1:40). 
c
 Defined as females >14 units/week, males >21 unis/week or patient disclosed history of a current or prior alcohol problem 
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Figure legend 
Figure 1. Identification of liver disease 
ALP alkaline phosphatase; ALT alanine aminotransferase; AST aspartate aminotransferase; CLD chronic liver 
disease; CS-CLD clinically significant chronic liver disease; GGT gamma glutamyl transferase; HCC 
hepatocellular carcinoma; USS ultrasound scan. 
Alcohol excess was defined as females >14 units/week, males >21 unis/week or patient disclosed history of a 
current or prior alcohol problem.   
Use of potentially hepatotoxic medication was defined as the use of non-topical glucocorticoids for >1 week, 
isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the year 1 clinic.  Strongly 
positive autoantibodies were defined as ASMA titre >1:160 or AMA titre >1:40. 
Figure 2. Patient flowcahrts 
AFP alpha feto protein; ALD alcoholic liver disease; ALT alanine aminotransferase; AST aspartate 
aminotransferase; CS-CLD clinically significant chronic liver disease; HA hyaluronic acid; HBV hepatitis B 
virus; LFTs liver function tests; NAFLD non-alcoholic fatty liver disease; PBC primary biliary cirrhosis 
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Figures 
Figure 1.  Identification of liver disease 
 
 
 
 
 
 
 
 
A. Specialist Hepatology referral criteria, any of: 
x routine liver enzyme tests above the laboratory ULN (ALT >50 U/L, AST >45 U/L, GGT >55 U/L, ALP >125 
U/L) 
x AST:ALT ratio >1 
x hyaluronic acid >100 microg/L (in the absence of known joint disease) 
x positive autoantibodies (any of anti-nuclear antibody, anti-smooth muscle antibody, anti-mitochondrial 
antibody) 
x ferritin >1000 ng/mL 
x alpha-feto protein >6 ng/mL 
x positive hepatitis B or C serology) 
x spleen >13cm (in the absence of known haematological cause) 
x platelets <150 x109/L (in the absence of known haematological cause) 
x suspected cirrhosis on USS 
B. Health record and individual case note verification: 
x possible cases were identified from year 1and year 4 clinic patient self-reported questionnaires; data 
linkage to ICD-9/10 and OPCS coding within SMR01 general and acute inpatient discharge records (at NHS 
National Services Scotland, Information Services Division) in July 2008 and July 2011; non-attenders at the 
year 4 clinic were sent a postal questionnaire and if no response was received a modified questionnaire 
was sent to the General Practitioner.   
x definite ĐĂƐĞƐǁĞƌĞĐŽŶĨŝƌŵĞĚƚŚƌŽƵŐŚƚŚĞƌĞǀŝĞǁŽĨĂůůƉĂƚŝĞŶƚƐ ?ĞůĞĐƚƌŽŶŝĐƐĞĐŽŶĚĂry care medical records 
(TrakCare, InterSystems Corp., Cambridge, USA) until 31 December 2013 in order to verify all possible 
diagnoses and to identify any additional CLD. 
C. Clinically significant chronic liver disease definition: 
x Definite (prevalent or incident) CS-CLD was a composite outcome defined as a diagnosis of cirrhosis, HCC 
(with confirmatory radiology) or gastro-oesophageal varices (with confirmatory endoscopy) recorded in 
ƚŚĞƉĂƚŝĞŶƚƐ ?ŵĞĚŝĐĂůƌĞĐŽƌĚƐ ? 
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Figure 2. Patient flowcharts 
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